iRadimed (NASDAQ:IRMD) CEO Sells $501,900.00 in Stock

iRadimed Corporation (NASDAQ:IRMD) CEO Roger Susi sold 5,000 shares of the stock in a transaction on Monday, March 23rd. The stock was sold at an average price of $100.38, for a total value of $501,900.00. Following the transaction, the chief executive officer directly owned 2,235,000 shares in the company, valued at approximately $224,349,300. This represents a 0.22% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

iRadimed Stock Up 0.8%

Shares of NASDAQ:IRMD traded up $0.81 during midday trading on Wednesday, reaching $101.78. The company’s stock had a trading volume of 52,623 shares, compared to its average volume of 74,394. The firm has a market cap of $1.30 billion, a price-to-earnings ratio of 58.16 and a beta of 1.12. iRadimed Corporation has a 1 year low of $47.48 and a 1 year high of $107.90. The business has a 50 day moving average price of $100.53 and a 200 day moving average price of $90.14.

iRadimed (NASDAQ:IRMD) last released its earnings results on Tuesday, February 10th. The medical equipment provider reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.49 by $0.05. iRadimed had a return on equity of 23.83% and a net margin of 26.82%.The firm had revenue of $22.69 million for the quarter, compared to the consensus estimate of $21.60 million. iRadimed has set its Q1 2026 guidance at 0.440-0.480 EPS and its FY 2026 guidance at 2.060-2.210 EPS. Sell-side analysts anticipate that iRadimed Corporation will post 1.66 earnings per share for the current fiscal year.

iRadimed Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, March 6th. Stockholders of record on Monday, February 23rd were issued a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a dividend yield of 0.8%. The ex-dividend date was Monday, February 23rd. This is an increase from iRadimed’s previous quarterly dividend of $0.17. iRadimed’s payout ratio is currently 45.71%.

Hedge Funds Weigh In On iRadimed

Several hedge funds and other institutional investors have recently modified their holdings of IRMD. Vanguard Group Inc. increased its position in iRadimed by 1.0% during the 3rd quarter. Vanguard Group Inc. now owns 566,507 shares of the medical equipment provider’s stock worth $40,313,000 after purchasing an additional 5,475 shares in the last quarter. Geode Capital Management LLC lifted its position in iRadimed by 6.5% during the second quarter. Geode Capital Management LLC now owns 261,386 shares of the medical equipment provider’s stock valued at $15,630,000 after buying an additional 15,996 shares in the last quarter. T. Rowe Price Investment Management Inc. lifted its position in iRadimed by 410.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 255,887 shares of the medical equipment provider’s stock valued at $24,893,000 after buying an additional 205,783 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in iRadimed by 1.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 217,129 shares of the medical equipment provider’s stock worth $21,123,000 after buying an additional 2,578 shares during the period. Finally, Ranger Investment Management L.P. grew its stake in iRadimed by 7.4% during the second quarter. Ranger Investment Management L.P. now owns 214,840 shares of the medical equipment provider’s stock worth $12,845,000 after buying an additional 14,730 shares during the period. 92.34% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

IRMD has been the subject of a number of recent analyst reports. Lake Street Capital restated a “buy” rating and issued a $120.00 target price on shares of iRadimed in a report on Wednesday, February 11th. Weiss Ratings reiterated a “buy (b-)” rating on shares of iRadimed in a report on Monday, December 29th. Finally, Roth Mkm reissued a “buy” rating and set a $120.00 price objective on shares of iRadimed in a research note on Tuesday, February 10th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, iRadimed presently has an average rating of “Moderate Buy” and an average target price of $120.00.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.